Inhibrx Q1 net loss $43.3M; cash $216.5M after $100M loan; data readouts expected in 2025

Inhibrx Biosciences, Inc.

2025-Q1 EPS reported -$2.80

Net loss $43.3M ($2.80/share) vs $78.7M ($5.77/share) in Q1 2024.
Cash $216.5M at March 31, 2025, up from $152.6M after $100M loan from Oxford Finance in Jan 2025.
INBRX-109 registration-enabling Phase 2 data for chondrosarcoma expected Q3 2025; CRC cohort data also Q3 2025.
INBRX-106 Phase 2/3 data for HNSCC with Keytruda expected Q4 2025; interim NSCLC data Q4 2025.
R&D expenses fell to $36.9M from $63.9M due to spin-off of INBRX-101 program in Q2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.